215 related articles for article (PubMed ID: 17612853)
41. A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia.
Taylor D; Hayhurst K; Kerwin R
Int Clin Psychopharmacol; 2007 May; 22(3):133-6. PubMed ID: 17414738
[TBL] [Abstract][Full Text] [Related]
42. Pharmacotherapy of behavioral and psychological symptoms of dementia: a review of atypical antipsychotics.
Daiello LA; Beier MT; Hoffmann VP; Kennedy JS
Consult Pharm; 2003 Feb; 18(2):138-52, 155-7. PubMed ID: 16563055
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis.
McIntyre RS; Cragin L; Sorensen S; Naci H; Baker T; Roussy JP
J Eval Clin Pract; 2010 Aug; 16(4):744-55. PubMed ID: 20545800
[TBL] [Abstract][Full Text] [Related]
44. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?
Luchins DJ
Adm Policy Ment Health; 2006 Sep; 33(5):541-3. PubMed ID: 16688482
[TBL] [Abstract][Full Text] [Related]
45. Evaluating clinical trial data: outcome measures.
Conley RR
J Clin Psychiatry; 2001; 62 Suppl 9():23-6; discussion 27-8. PubMed ID: 11379827
[TBL] [Abstract][Full Text] [Related]
46. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
[TBL] [Abstract][Full Text] [Related]
47. New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update.
Caccia S
Curr Opin Investig Drugs; 2002 Jul; 3(7):1073-80. PubMed ID: 12186270
[TBL] [Abstract][Full Text] [Related]
48. Safety evaluation of zotepine for the treatment of schizophrenia.
Riedel M; Musil R; Seemüller F; Spellmann I; Möller HJ; Schennach-Wolff R
Expert Opin Drug Saf; 2010 Jul; 9(4):659-66. PubMed ID: 20486863
[TBL] [Abstract][Full Text] [Related]
49. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis.
Chung AK; Chua SE
J Psychopharmacol; 2011 May; 25(5):646-66. PubMed ID: 20826552
[TBL] [Abstract][Full Text] [Related]
50. Evidence-based pharmacotherapy of schizophrenia.
Emsley R; Oosthuizen P
Int J Neuropsychopharmacol; 2004 Jun; 7(2):219-38. PubMed ID: 15043765
[TBL] [Abstract][Full Text] [Related]
51. Improving patient outcomes in schizophrenia: achieving remission.
Nasrallah HA; Lasser R
J Psychopharmacol; 2006 Nov; 20(6 Suppl):57-61. PubMed ID: 17046987
[TBL] [Abstract][Full Text] [Related]
52. [Functionality as a goal in the treatment of schizophrenia].
García B;
Actas Esp Psiquiatr; 2002; 30(5):312-25. PubMed ID: 12372228
[TBL] [Abstract][Full Text] [Related]
53. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.
Weiss EM; Bilder RM; Fleischhacker WW
Psychopharmacology (Berl); 2002 Jun; 162(1):11-7. PubMed ID: 12107611
[TBL] [Abstract][Full Text] [Related]
54. [Haematological abnormalities during treatment with atypical antipsychotics].
Thome J; Kopf D
Psychiatr Prax; 2005 May; 32(4):167-71. PubMed ID: 15852208
[TBL] [Abstract][Full Text] [Related]
55. Sex selection bias in schizophrenia antipsychotic trials.
Chaves AC; Seeman MV
J Clin Psychopharmacol; 2006 Oct; 26(5):489-94. PubMed ID: 16974190
[TBL] [Abstract][Full Text] [Related]
56. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.
Tandon R; Jibson MD
Int J Psychiatry Clin Pract; 2005; 9(3):204-12. PubMed ID: 24937792
[TBL] [Abstract][Full Text] [Related]
57. Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics.
Oliveira IR; Nunes PM; Coutinho DM; Sena EP
Braz J Psychiatry; 2009 Mar; 31(1):52-6. PubMed ID: 19506777
[TBL] [Abstract][Full Text] [Related]
58. Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials.
Pecenak J
Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():49-70. PubMed ID: 17262007
[TBL] [Abstract][Full Text] [Related]
59. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Kissling W; Davis JM; Leucht S
Schizophr Bull; 2012 Jan; 38(1):167-77. PubMed ID: 20513652
[TBL] [Abstract][Full Text] [Related]
60. Clinical effectiveness in first-episode patients.
Ohlsen RI; O'Toole MS; Purvis RG; Walters JT; Taylor TM; Jones HM; Pilowsky LS
Eur Neuropsychopharmacol; 2004 Nov; 14 Suppl 4():S445-51. PubMed ID: 15572263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
